EDRN Prostate and Genitourinary Cancers Collaborative Group Meeting (DRAFT)

Tuesday, September 24, 2024 (2:30 p.m. – 5:45 p.m.)

Room: College of Nursing, Room 2018

Co-chair: Jeffrey Tosoian, MD, MPH, Vanderbilt University Medical Center

Co-chair: Martin Sanda, MD, Emory University

DMCC Statistician: Yingye Zheng, PhD, Fred Hutchinson Cancer Center

DMCC Staff: Kristin Rodgers, Fred Hutchinson Cancer Center

NCI Program Directors: Indu Kohaar, PhD, National Cancer Institute (Primary), Richard Mazurchuk, PhD, Guillermo Marquez, PhD

Agenda

Central Daylight Time	Agenda Item
2:30 p.m. – 2:35 p.m.	Welcome Indu Kohaar, PhD, National Cancer Institute
2:35 p.m. – 2:55 p.m.	Pathology-Based Deep Learning Tools to Personalize Treatment Decisions 01: Trevor Royce MD, MS, MPH, FASCO, Senior Medical Director, ArteraAI (Remote Presenter)
2:55 p.m. – 3:55 p.m.	Progress Update by Biomarker Characterization Centers Presentation by BDLs and BRLs of BCCs on the approaches they are currently using, completed aims, and current aims
2:55 p.m. – 3:15 p.m.	Michigan-VUMC Biomarker Characterization Center
2:55 p.m. – 3:00 p.m. 3:00 p.m. – 3:05 p.m. Q&A	02: BRL Jeffrey Tosoian, MD, MPH, Vanderbilt University Medical Center Q&A
3:05 p.m. – 3:10 p.m. 3:10 p.m. – 3:15 p.m. Q&A	03: BDL Arul Chinnaiyan MD, University of Michigan Q&A
3:15 p.m. – 3:35 p.m.	Virginia-UCLA-Toronto Biomarker Characterization Center
3:15 p.m. – 3:20 p.m. 3:20 p.m. – 3:25 p.m. Q&A	04: BRL Thomas Kislinger, PhD, University Heath Network - University of Toronto Q&A
3:25 p.m. – 3:30 p.m. 3:30 p.m. – 3:35 p.m. Q&A	05: BDL Paul Boutros, PhD, University of California Los Angeles Q&A
3:35 p.m. – 3:55 p.m.	Johns Hopkins Biomarker Characterization Center
3:35 p.m. – 3:40 p.m. 3:40 p.m. – 3:45 p.m. Q&A	06: BRL Zhen Zhang, PhD, Johns Hopkins University School of Medicine Q&A
3:45 p.m. – 3:50 p.m. 3:50 p.m. – 3:55 p.m. Q&A	07: BDL Mamie Lih, PhD, Johns Hopkins University Q&A
3:55 p.m. – 4:15 p.m.	Progress Update by Clinical Validation Center Presentation by CVC to lay out the various resources (specimens/imaging/clinical outcomes) of potential usage to others (15 min, 5 min Q&A).
3:55 p.m. – 4:10 p.m. 4:10 p.m. – 4:15 p.m. Q&A	Emory-UAB-UTSW Prostate Cancer Biomarker and Imaging Validation Alliance 08: Martin Sanda, MD, Emory University
4:15 p.m. – 4:30 p.m. 4:30 p.m. – 4:35 p.m. Q&A	NCI EDRN MRI Biomarker Study and Reference Set (P-MRI) 09: John Wei, MD, MS, University of Michigan
4:35 p.m. – 4:45 p.m.	Break
4:45 p.m. – 5:45 p.m.	Open discussion on new perspectives and focus areas that can be coordinated across the group including BCCs and CVCs *Moderators:* Jeffrey Tosoian, MD, MPH, Vanderbilt University Medical Center Martin Sanda, MD, Emory University What specific approaches and biomarkers appear most promising? Which approaches and biomarkers are ready to be moved to validation? Discuss cross-center collaborations that will facilitate validation of these approaches and biomarkers -considering available and developing data from CVCs, references sets.
5:45 p.m.	Adjourn

Central Daylight Time

Agenda Item

2:30 p.m. – 2:35 p.m.

Welcome

Indu Kohaar, PhD, National Cancer Institute

2:35 p.m. – 2:55 p.m.

Pathology-Based Deep Learning Tools to Personalize Treatment Decisions

01: Trevor Royce MD, MS, MPH, FASCO, Senior Medical Director, ArteraAI (Remote Presenter)

2:55 p.m. – 3:55 p.m.

Progress Update by Biomarker Characterization Centers

Presentation by BDLs and BRLs of BCCs on the approaches they are currently using, completed aims, and current aims

2:55 p.m. – 3:15 p.m.

Michigan-VUMC Biomarker Characterization Center

2:55 p.m. – 3:00 p.m.

3:00 p.m. – 3:05 p.m. Q&A

02: BRL Jeffrey Tosoian, MD, MPH, Vanderbilt University Medical Center

3:05 p.m. – 3:10 p.m.

3:10 p.m. – 3:15 p.m. Q&A

03: BDL Arul Chinnaiyan MD, University of Michigan

Q&A

3:15 p.m. – 3:35 p.m.

Virginia-UCLA-Toronto Biomarker Characterization Center

3:15 p.m. – 3:20 p.m.

3:20 p.m. – 3:25 p.m. Q&A

04: BRL Thomas Kislinger, PhD, University Heath Network - University of Toronto

3:25 p.m. – 3:30 p.m.

3:30 p.m. – 3:35 p.m. Q&A

05: BDL Paul Boutros, PhD, University of California Los Angeles

Q&A

3:35 p.m. – 3:55 p.m.

Johns Hopkins Biomarker Characterization Center

3:35 p.m. – 3:40 p.m.

3:40 p.m. – 3:45 p.m. Q&A

06: BRL Zhen Zhang, PhD, Johns Hopkins University School of Medicine

3:45 p.m. – 3:50 p.m.

3:50 p.m. – 3:55 p.m. Q&A

07: BDL Mamie Lih, PhD, Johns Hopkins University

3:55 p.m. – 4:15 p.m.

Progress Update by Clinical Validation Center

Presentation by CVC to lay out the various resources (specimens/imaging/clinical outcomes) of potential usage to others (15 min, 5 min Q&A).

3:55 p.m. – 4:10 p.m.

4:10 p.m. – 4:15 p.m. Q&A

Emory-UAB-UTSW Prostate Cancer Biomarker and Imaging Validation Alliance

08: Martin Sanda, MD, Emory University

4:15 p.m. – 4:30 p.m.

4:30 p.m. – 4:35 p.m. Q&A

NCI EDRN MRI Biomarker Study and Reference Set (P-MRI)

09: John Wei, MD, MS, University of Michigan

4:35 p.m. – 4:45 p.m.

Break

4:45 p.m. – 5:45 p.m.

Open discussion on new perspectives and focus areas that can be coordinated across the group including BCCs and CVCs

Moderators:

Jeffrey Tosoian, MD, MPH, Vanderbilt University Medical Center
Martin Sanda, MD, Emory University

What specific approaches and biomarkers appear most promising? Which approaches and biomarkers are ready to be moved to validation?
Discuss cross-center collaborations that will facilitate validation of these approaches and biomarkers -considering available and developing data from CVCs, references sets.

5:45 p.m.

Adjourn